Fundraising FoxAlta Partners — 2024 Investments
4 investments dated 2024 · listed companies and verified rows first · show all
Tyra is developing oral dabogratinib, a small-molecule therapy being evaluated in clinical studies for skeletal dysplasia and urologic cancers.
BiotechHealthtechCarlsbad, US
Todd Harris, Ph.D.(Executive Officer, Director)Hiroomi Tada, M.D., Ph.D.(Executive Officer)Daniel Bensen(Executive Officer)inAlan Fuhrman(Executive Officer)inTodd Harris(President, Chief Executive Officer and Director)inBhavesh Ashar(Chief Operating Officer)in
Co-investorsBioBritNextech InvestCanaan PartnersRA Capital
Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.
BiotechDeep TechMedical DevicesWatertown, US
Dmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)Marc-Olivier Turgeon(Director)in
BoardAleks Radovic-Moreno(Director)in
Board seatDan Janney· per SEC Form D
Co-investorsDolby Family VenturesLongwood FundMission BiocapitalService Provider CapitalForbion
Lassen Therapeutics is a biotechnology company developing therapeutics targeting IL-11, with a pipeline focused on immune and fibrotic diseases.
Biotech
David King(Co-Founder & CSO)inMaria Fardis(CEO)inCadmus C. Rich(Chief Medical Officer)inElaine Stracker(General Counsel)in
Co-investorsCatalio Capital Management, LPDC Investment PartnersFrazier Life SciencesLongitude CapitalLongwood FundBiotechnology Value Fund+2 more
Transcarent operates a generative AI-powered health and care platform that combines medical, pharmacy, and point solutions into a single member experience, helping people navigate the healthcare system and access on-demand care.
AI & Machine LearningDigital HealthHealthtechDenver, US
Glen Tullman(Founder)inStephanie Peng(Executive Officer)Lee Shapiro(Executive Officer, Director)Ken Frazier(Director)Holly Maloney(Director)Hemant Taneja(Director)
Co-investors7wire VenturesCorewell Health VenturesGeneral CatalystGeodesic CapitalGreatPoint VenturesHuman Capital+9 more
.png)
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.